Ownership and insider activity for None (CGTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist.
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.9M | $5.2M | $54.7M | $41.6M | $29.9M | $25.0M | $36.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $4.1M | $1.2M | $2.3M | $3.7M | $1.3M | $2.7M | $9.9M |
| Inventory | $117000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $7.2M | $6.9M | $59.0M | $47.6M | $34.2M | $29.6M | $48.0M |
| Property, Plant & Equipment | $299000 | $211000 | $145000 | $1.0M | $941000 | $679000 | $399000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $7.5M | $7.1M | $59.1M | $50.4M | $35.2M | $30.2M | $48.4M |
| Accounts Payable | $2.4M | $2.0M | $4.2M | $3.2M | $3.7M | $2.0M | $1.1M |
| Short-term Debt | 0 | 0 | 0 | $634000 | $544000 | $279000 | $307000 |
| Total Current Liabilities | $3.7M | $3.2M | $7.9M | $7.8M | $10.2M | $11.1M | $13.9M |
| Long-term Debt | $6.9M | $12.9M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $65.9M | $75.3M | $7.9M | $10.2M | $10.7M | $11.5M | $14.1M |
| Retained Earnings | -$58.2M | -$68.2M | -$94.0M | -$115.4M | -$141.2M | -$175.2M | -$198.6M |
| Total Equity | -$58.4M | -$68.2M | $51.3M | $40.2M | $24.5M | $18.8M | $34.3M |
| Total Debt | $6.9M | $12.9M | 0 | $1.5M | $1.2M | $814000 | $638000 |
| Net Debt | $4.0M | $7.7M | -$54.7M | -$40.1M | -$28.7M | -$24.2M | -$36.2M |
| Working Capital | $3.5M | $3.7M | $51.1M | $39.9M | $24.1M | $18.4M | $34.1M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.99 |
Related companies: AGEN · ATOS · GLSI · IRD · MCRB · SEER · SPRO
More sections of CGTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks